Literatur
- 1
Regier D A, Farmer M E, Rae D S, Locke B Z, Keith S J, Judd L L, Goodwin F K.
Comorbidity of mental disorders with alcohol and other drug abuse. Results from the
Epidemiologic Catchment Area (ECA) Study.
JAMA.
1990;
264
2511-2518
- 2 Hubbard J R, Martin P R. Substance abuse in the mentally and physically disabled:
an overview. In: Hubbard JR, Martin PR (Hrsg). Substance abuse in the mentally and
physically disabled. New York, Basel: Marcel Dekker 2001: 1-10
- 3
Cantor-Graae E, Nordstrom L G, McNeil T F.
Substance abuse in schizophrenia: a review of the literature and a study of correlates
in Sweden.
Schizophr Res.
2001;
48
69-82
- 4
Drake R E, Mueser K T.
Psychosocial approaches to dual diagnosis.
Schizophr Bull.
2000;
26
105-118
- 5
Lammertink M, Lohrer F, Kaiser R, Hambrecht M, Pukrop R.
Differences in substance abuse patterns: multiple drug abuse alone versus schizophrenia
with multiple drug abuse.
Acta Psychiatr Scand.
2001;
104
361-366
- 6
Duke P J, Pantelis C, McPhillips M A, Barnes T R.
Comorbid non-alcohol substance misuse among people with schizophrenia: epidemiological
study in central London.
Br J Psychiatry.
2001;
179
509-513
- 7
Dixon L.
Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes.
Schizophr Res.
1999;
35 Suppl
S93-100
- 8
Mueser K T, Yarnold P R, Rosenberg S D, Swett Jr C, Miles K M, Hill D.
Substance use disorder in hospitalized severely mentally ill psychiatric patients:
prevalence, correlates, and subgroups.
Schizophr Bull.
2000;
26
179-192
- 9
Dervaux A, Bayle F J, Laqueille X, Bourdel M C, Le Borgne M H, Olie J P, Krebs M O.
Is substance abuse in schizophrenia related to impulsivity, sensation seeking, or
anhedonia?.
Am J Psychiatry.
2001;
158
492-494
- 10
Mueser K T, Drake R E, Wallach M A.
Dual diagnosis: a review of etiological theories.
Addict Behav.
1998;
23
717-734
- 11
Blanchard J J, Brown S A, Horan W P, Sherwood A R.
Substance use disorders in schizophrenia: review, integration, and a proposed model.
Clin Psychol Rev.
2000;
20
207-234
- 12
Chambers R A, Krystal J H, Self D W.
A neurobiological basis for substance abuse comorbidity in schizophrenia.
Biol Psychiatry.
2001;
50
71-83
- 13 Gouzoulis-Mayfrank E. Komorbidität Psychose und Sucht - Von den Grundlagen zur
Praxis - Mit Manual für Psychoedukatives Training. Darmstadt: Steinkopff 2003
- 14
Hambrecht M, Haefner H.
H. Substance abuse and the onset of schizophrenia.
Biol Psychiatry.
1996;
40
1155-1163
- 15
Linszen D H, Dingemans P M, Lenior M E.
Cannabis abuse and the course of recent-onset schizophrenic disorders.
Arch Gen Psychiatry.
1994;
51
273-279
- 16
Andreasson S, Allebeck P, Engstrom A, Rydberg U.
Cannabis and schizophrenia. A longitudinal study of Swedish conscripts.
Lancet.
1987;
2
1483-1486
- 17 Lee M A, Meltzer H Y. Substance abuse in schizophrenia. Biological factors mediating
comorbidity and the potential role of atypical antipsychotic drugs. In: Hubbard JR,
Martin PR (Hrsg). Substance abuse in the mentally and physically disabled. New York:
Marcel Dekker 2001: 77-101
- 18
Hunt G E, Bergen J, Bashir M.
Medication compliance and comorbid substance abuse in schizophrenia: impact on community
survival 4 years after a relapse.
Schizophrenia Research.
2002;
54
253-264
- 19 Ziedonis D M, D'Avanzo K. Schizophrenia and Substance abuse. In: Kranzler HR, Rounsaville
BJ (Hrsg). Dual diagnosis and treatment. New York: Marcel Dekker 1998: 427-465
- 20
Drake R E, Mercer-McFadden C, Mueser K T, McHugo G J, Bond G R.
Review of integrated mental health and substance abuse treatment for patients with
dual disorders.
Schizophr Bull.
1998;
24
589-608
- 21
Drake R E, Mueser K T, Brunette M F, McHugo G J.
A review of treatments for people with severe mental illnesses and co-occurring substance
use disorders.
Psychiatr Rehabil J.
2004;
27
360-374
- 22 Bechdolf A, Pohlmann B, Reck C, Klosterkötter J, Gouzoulis-Mayfrank E. Motivationsbehandlung
bei Patienten mit der Doppeldiagnose Psychose und Sucht: Eine Übersicht. Fortschr
Neurol Psychiat 2005, in Druck
- 23
Bennett M E, Bellack A S, Gearon J S.
Treating substance abuse in schizophrenia. An initial report.
J Subst Abuse Treat.
2001;
20
163-175
- 24
Barrowclough C, Haddock G, Tarrier N, Lewis S W, Moring J, O'Brien R, Schofield N,
McGovern J.
Randomized controlled trial of motivational interviewing, cognitive behavior therapy,
and family intervention for patients with comorbid schizophrenia and substance use
disorders.
Am J Psychiatry.
2001;
158
1706-1713
- 25 Dámelio R, Wodbrock T, Klein T, Behrendt B, Falkai P, Oest M. GOAL - Gesund und
ohne Abhängigkeit leben. Ein integrativer Ansatz zur Therapie von Patienten mit einer
Psychose aus dem schizophrenen Formenkreis und komorbidem Substanzkonsum. In: Behrendt
B, Schaub A (Hrsg). Psychoedukation und Selbstmanagement. Verhaltenstherapeutische
Ansätze zur Krankheitsbewältigung für die klinische Praxis. Tübingen: DGVT Verlag
2004
- 26
Mueser K T, Fox L.
A family intervention program for dual disorders.
Community Ment Health J.
2002;
38
253-270
- 27
Dixon L, Adams C, Lucksted A.
Update on family psychoeducation for schizophrenia.
Schizophr Bull.
2000;
26
5-20
- 28
Buckley P F.
Substance abuse in schizophrenia: a review.
J Clin Psychiatry.
1998;
59 Suppl 3
26-30
- 29
Krystal J H, D'Souza D C, Madonick S, Petrakis I L.
Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients.
Schizophrenia Research.
1999;
35 Suppl
S35-S49
- 30
Potvin S, Stip E, Roy J Y.
Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards
testable hypotheses.
Int Clin Psychopharmacol.
2003;
18
121-132
- 31
Noordsy D L, Green A I.
Pharmacotherapy for schizophrenia and co-occurring substance use disorders.
Curr Psychiatry Rep.
2003;
5
340-346
- 32
Green A I.
Schizophrenia and comorbid substance use disorder: effects of antipsychotics.
J Clin Psychiatry.
2005;
66 Suppl 6
21-26
- 33
Brown E S, Nejtek V A, Perantie D C, Rajan T N, Rush A J.
Cocaine and amphetamine use in patients with psychiatric illness: a randomized trial
of typical antipsychotic continuation or discontinuation.
J Clin Psychopharmacol.
2003;
23
384-388
- 34
Zimmet S V, Strous R D, Burgess E S, Kohnstamm S, Green A I.
Effects of clozapine on substance use in patients with schizophrenia and schizoaffective
disorder: a retrospective survey.
J Clin Psychopharmacol.
2000;
20
94-98
- 35
Drake R E, Xie H, McHugo G J, Green A I.
The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia.
Schizophr Bull.
2000;
26
441-449
- 36
Potvin S, Stip E, Roy J Y.
The effect of quetiapine on cannabis use in 8 psychosis patients with drug dependency.
Can J Psychiatry.
2004;
49
711
- 37
Warsi M, Sattar S P, Bhatia S C, Petty F.
Aripiprazole reduces alcohol use.
Can J Psychiatry.
2005;
50
244
- 38
Beresford T P, Clapp L, Martin B, Wiberg J L, Alfers J, Beresford H F.
Aripiprazole in schizophrenia with cocaine dependence: a pilot study.
J Clin Psychopharmacol.
2005;
25
363-366
- 39
Brown E S, Jeffress J, Liggin J D, Garza M, Beard L.
Switching outpatients with bipolar or schizoaffective disorders and substance abuse
from their current antipsychotic to aripiprazole.
J Clin Psychiatry.
2005;
66
756-760
- 40
Sayers S L, Campbell E C, Kondrich J, Mann S C, Cornish J, O'Brien C, Caroff S N.
Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol.
J Nerv Ment Dis.
2005;
193
379-386
- 41
Green A I, Burgess E S, Dawson R, Zimmet S V, Strous R D.
Alcohol and cannabis use in schizophrenia: effects of clozapine and risperidone.
Schizophrenia Research.
2003;
60
81-85
- 42
Levin F R, Evans S M, Coomaraswammy S, Collins E D, Regent N, Kleber H D.
Flupenthixol treatment for cocaine abusers with schizophrenia: a pilot study.
Am J Drug Alcohol Abuse.
1998;
24
343-360
- 43
Soyka M, Aichmuller C, Bardeleben U, Beneke M, Glaser T, Hornung-Knobel S, Wegner U.
Flupenthixol in relapse prevention in schizophrenics with comorbid alcoholism: results
from an open clinical study.
Eur Addict Res.
2003;
9
65-72
- 44
Maxwell S, Shinderman M S.
Use of naltrexone in the treatment of alcohol use disorders in patients with concomitant
major mental illness.
J Addict Dis.
2000;
19
61-69
- 45
Petrakis I L, O'Malley S, Rounsaville B, Poling J, Hugh-Strong C, Krystal J H.
Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with
schizophrenia.
Psychopharmacology.
2004;
172
291-297
- 46
Petrakis I L, Poling J, Levinson C, Nich C, Carroll K, Rounsaville B.
Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric
disorders.
Biol Psychiatry.
2005;
57
1128-1137
Univ.-Prof. Dr. med. Euphrosyne Gouzoulis-Mayfrank
Klinik und Poliklinik für Psychiatrie und PsychotherapieKlinikum der Universität zu
Köln
Kerpener Straße 62
50931 Köln
Email: e.gouzoulis@uni-koeln.de
